Articles related to Endocrinology, Diabetes, Metabolism

Versus placebo, pemafibrate yielded a more than 25% greater reduction in triglycerides, VLDL, remnant cholesterol, and apolipoprotein C-III in patients with type 2 diabetes. However, there was no reduction versus placebo in MI, ischemic stroke, need for coronary revascularization, or CV death.

These specialties had the highest proportion of doctors still making student loan payments, per the 2022 Medscape report: Emergency Medicine (31%) Physical Medicine & Rehabilitation (31%) Pediatrics (31%) Neurology (28%) Otolaryngology (28%) Family Medicine (28%) For the least debt-burdened: Pulmonary Medicine (10%) Public Health & Preventive Medicine (11%) Rheumatology (12%) Diabetes & Endocrinology (15%) Dermatology (16%) Cardiology (16%)

In comparison to 72% of patients who received placebo, 45% of those who received teplizumab-mzwv (Tzield, Provention Bio) over the course of a median follow-up of 51 months were found to have stage 3 type 1 diabetes. Teplizumab-mzwv appeared to delay the onset of type 1 diabetes by about two years, as the median time from randomization to diagnosis of stage 3 diabetes was 50 months in the teplizumab-mzwv group and 25 months in the placebo group.

MDLinx compiled a reading list of captivating books that have nothing to do with medicine—but might just help physicians realize some things about their work — and life.

Looking at 2,500 case patients mapped to more than 45,000 controls, the hazard ratio for all thyroid cancers in GLP-1 users was 1.46. The hazard ratio for developing thyroid cancer with DPP-4 inhibitors was 1.1. GLP-1 receptors are present in normal and cancerous thyroid cells.

This case review highlights the differential diagnosis with lesions of this kind, together with management and clinical pearls.